Can residual paralysis be avoided?: A critical appraisal of the use of sugammadex

Eur J Anaesthesiol. 2015 Oct;32(10):663-5. doi: 10.1097/EJA.0000000000000294.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Neuromuscular Blockade / adverse effects*
  • Neuromuscular Blocking Agents / adverse effects*
  • Neuromuscular Blocking Agents / antagonists & inhibitors
  • Paralysis / etiology
  • Paralysis / prevention & control
  • Sugammadex
  • gamma-Cyclodextrins / administration & dosage*

Substances

  • Neuromuscular Blocking Agents
  • gamma-Cyclodextrins
  • Sugammadex